People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Healthtech, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Supira Medical, Inc. | — | Healthtech | Series D+ | $220.7M | $1.1B | 2017 |
| Akura Medical, Inc. | — | Healthtech | Series C | $94.8M | $299.6M | 2021 |
| Tioga Cardiovascular, Inc. | — | Other Health Care | Series B | $69.8M | $105.7M | 2019 |
| Adona Medical, Inc. | — | Healthtech | Series B | $54.1M | $91.1M | 2020 |
| Atia Vision, Inc. | — | Biotechnology | Series B | $51.0M | $466.9M | 2018 |
| Myra Vision, Inc. | — | Other Health Care | Series B | $36.0M | $108.8M | 2019 |
| Laza Medical, Inc. | — | Biotechnology | Series B | $25.5M | $235.3M | 2023 |
| Apama Medical, Inc. | — | Healthtech | Series A | $14.3M | $297.4M | 2016 |
| NuVera Medical, Inc. | — | Biotechnology | Series A | $11.7M | $423.0M | 2017 |
| Maya Medical, Inc. | — | Other Health Care | Seed | $6.9M | $25.8M | 2010 |
AMR SALAHIEH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside AMR SALAHIEH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mariam Maghribi | 6 | 6 |
| BIHUA CHEN | 5 | 14 |
| Casey Gordon | 4 | 4 |
| Gautam Kainth | 3 | 3 |
| FARHAD KHOSRAVI | 2 | 14 |
| Henry Chen | 2 | 7 |
| MOTASIM SIRHAN | 2 | 2 |
| Robert Chang | 1 | 4 |
| Greg Casciaro | 1 | 4 |
| Rob Kuhling | 1 | 3 |
| Tara Butler, M.D. | 1 | 2 |
| Christopher Shen | 1 | 2 |
| Brian Fahey | 1 | 2 |
| David Garcia Voris | 1 | 1 |
| AMR SALAHEIH | 1 | 1 |
| Claudio Argento | 1 | 1 |
| David Voris | 1 | 1 |
| Murali Srivathsa | 1 | 1 |
| Michael Dineen | 1 | 1 |
| Nitin Salunke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.